{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:02:08Z","timestamp":1786114928301,"version":"build-2736575974"},"reference-count":22,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.esmoop.2026.107701","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:24:05Z","timestamp":1782858245000},"page":"107701","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Higher rates of immune-related adverse events in circulating tumor DNA (ctDNA)-negative patients following adjuvant checkpoint inhibitor therapy"],"prefix":"10.1016","volume":"11","author":[{"given":"T.","family":"Powles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Madjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0999-6185","authenticated-orcid":false,"given":"B.I.","family":"Balas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3012-4819","authenticated-orcid":false,"given":"C.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Essioux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tehrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mariathasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Heinzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4605-2020","authenticated-orcid":false,"given":"F.","family":"Arellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4233-5210","authenticated-orcid":false,"given":"R.","family":"Mohindra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5339-9906","authenticated-orcid":false,"given":"G.S.","family":"Chandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2026.107701_bib1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1158\/0008-5472.CAN-21-1718","article-title":"Current and future clinical applications of ctDNA in immuno-oncology","volume":"82","author":"Stadler","year":"2022","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.esmoop.2026.107701_bib2","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.107701_bib3","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2026.107701_bib4","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107701_bib5","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","article-title":"Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"85","author":"Powles","year":"2024","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107701_bib6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12885-023-10699-4","article-title":"ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C)","volume":"23","author":"Slater","year":"2023","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107701_bib7","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.annonc.2022.11.005","article-title":"Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer","volume":"34","author":"Turner","year":"2023","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107701_bib8","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.esmoop.2026.107701_bib9","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.107701_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005344","article-title":"Regulatory implications of ctDNA in immuno-oncology for solid tumors","volume":"11","author":"Vellanki","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107701_bib11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s13063-024-08186-7","article-title":"Survival analysis for AdVerse events with VarYing follow-up times (SAVVY): summary of findings and assessment of existing guidelines","volume":"25","author":"Rufibach","year":"2024","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107701_bib12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/19466315.2019.1575280","article-title":"Estimating the treatment effect in a subgroup defined by an early post-baseline biomarker measurement in randomized clinical trials with time-to-event endpoint","volume":"12","author":"Bornkamp","year":"2020","journal-title":"Stat Biopharm Res"},{"key":"10.1016\/j.esmoop.2026.107701_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1138305","article-title":"Baseline risk factors associated with immune related adverse events and atezolizumab","volume":"13","author":"Madjar","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2026.107701_bib14","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1038\/s41467-021-23661-4","article-title":"Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade","volume":"12","author":"Khan","year":"2021","journal-title":"Nat Commun"},{"issue":"7637","key":"10.1016\/j.esmoop.2026.107701_bib15","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer\u2013immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2026.107701_bib16","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1158\/2326-6066.CIR-21-1017","article-title":"Coming of age: human genomics and the cancer\u2013immune set point","volume":"10","author":"Hammer","year":"2022","journal-title":"Cancer Immunol Res"},{"issue":"22","key":"10.1016\/j.esmoop.2026.107701_bib17","doi-asserted-by":"crossref","first-page":"12288","DOI":"10.1073\/pnas.1922867117","article-title":"Polygenic risk for skin autoimmunity impacts immune checkpoint inhibitor blockade in bladder cancer","volume":"117","author":"Khan","year":"2020","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.esmoop.2026.107701_bib18","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1158\/1078-0432.CCR-21-0921","article-title":"Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with PD-1 blockade in non\u2013small cell lung cancer","volume":"27","author":"Luo","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.107701_bib19","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1038\/s41467-023-44512-4","article-title":"Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis","volume":"15","author":"Middha","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2026.107701_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009215","article-title":"Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma","volume":"12","author":"Borgers","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.esmoop.2026.107701_bib21","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41591-021-01623-z","article-title":"T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma","volume":"28","author":"Lozano","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2026.107701_bib22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12943-020-01274-7","article-title":"The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors","volume":"19","author":"Jin","year":"2020","journal-title":"Mol Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926016431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926016431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T22:51:52Z","timestamp":1785970312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926016431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2059702926016431"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107701","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Higher rates of immune-related adverse events in circulating tumor DNA (ctDNA)-negative patients following adjuvant checkpoint inhibitor therapy","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107701","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"107701"}}